Immunohistochemical changes in prostate cancer after androgen deprivation therapy

Molecular Urology

Volumn 4, Issue 3, 2000, Pages

  Bostwick, D G ^a   Klotz, L ^a   Garnick, M ^a  

^a BOSTWICK LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN RECEPTOR; ANTIANDROGEN; COLONY STIMULATING FACTOR 1; CYCLINE; CYTOKERATIN; ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 27; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 6; KERATIN; KI 67 ANTIGEN; MUCIN; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN P21; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

CELLULAR DISTRIBUTION; CONFERENCE PAPER; DISEASE ASSOCIATION; GENETIC STABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PLOIDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0033761328     PISSN: 10915362     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Clinical and pathological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma
2. Pathology of androgen deprivation therapy in prostate carcinoma: A comparative study of 173 patients
3. Prostate adenocarcinoma after androgen deprivation therapy: A comparative study of morphology, morphometry, immunohistochemistry, and DNA ploidy
4. Histopathologic effects of radiation and hormonal therapies on benign and malignant prostate tissues
5. Histopathological changes in androgen-deprived localized prostatic cancer: A study in total prostatectomy specimens
6. Total androgenic blockade: A review
7. Combination therapy for prostate cancer
8. New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens
9. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma
10. Finasteride dose-dependently reduces the proliferation rate of the LnCaP human prostatic cancer line in vitro
11. NM23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: Altered expression in combined androgen blockaded carcinomas
12. Leuprolide: A review of its pharmacology and therapeutic use in prostatic disorders
13. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy?
14. Minimal criteria for the diagnosis of prostate cancer on needle biopsy
15. Evaluating prostate needle biopsy: Therapeutic and prognostic importance
16. Gleason grading of prostatic needle biopsies: Correlation with grade in 316 matched prostatectomies
17. Morphologic changes in benign prostatic hyperplasia following chronic treatment with a 5-αreductase inhibitor finasteride: Comparison with combination endocrine therapy
18. Decrease of prostatic intraepithelial neoplasia (PIN) following androgen deprivation therapy in patients with stage T3 prostatic adenocarcinoma
19. Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation
20. Neoplasms of the prostate
21. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation: Specificity for steroids and antihormones
22. Chemoprevention of rat prostate carcinogenesis by use of finasteride or Casodex
23. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostate carcinoma: A randomized study
24. Endocrine profiles during administration of the new nonsteroidal anti-androgen Casodex in prostate cancer
25. Androgen receptor mutations
26. Androgen receptor alterations in prostatic carcinoma
27. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
28. Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence
29. Hormone-refractory (D3) prostate cancer: Refining the concept
30. Stability of the glycoprotein A-80 in prostatic carcinomas subsequent to androgen deprivation therapy
31. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues
32. Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma
33. Tissue prostate-specific antigen and androgen receptor immunoreactivity in prostate cancer biopsies before, during and after neo-adjuvant androgen deprivation followed by radiotherapy
34. Androgens regulate the expression of proliferating cell nuclear antigen posttranscriptionally in the human prostate cancer cell line, LnCaP
35. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation
36. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: Prognostic significance of p21/WAF1/CIP1 expression
37. The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer
38. Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: Evidence of self-renewal of luminal cells
39. Androgen receptor expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human prostate: An immunohistochemical and in situ hybridization study
40. Immunohistochemical analysis of Ki-67 antigen and Bcl-2 protein expression in prostate cancer: Effect of neoadjuvant hormonal therapy
41. Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy
42. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia
43. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
44. Amplification of the androgen receptor gene is associated with p53 mutation in hormone-refractory recurrent prostate cancer
45. Tumor angiogenesis in prostate tumors is decreased by preoperative hormonal deprivation
46. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer
47. Radiation injury of the normal and neoplastic prostate
48. Molecular biology of high grade prostatic intraepithelial neoplasia
49. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping
50. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persisent androgen-independent disease
51. Early castration-induced upregulation of transforming growth factor beta1 and its receptor is associated with tumor cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients
52. Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue microassays
53. Expression of cytokines enhancing the osteoclast activity, and parathyroid hormone-related protein in prostatic cancers before and after endocrine therapy: An immunohistochemical study
54. The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients
55. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy
56. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
57. Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy
58. Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer